Media OutReach
Sanofi sets Singapore Book of Records with the ‘Largest Mural of Magnetic Hands’ – a Public Pledge against Respiratory Syncytial Virus (RSV) in Nationwide Awareness Campaign
- Sanofi has achieved a new Singapore Book of Records milestone featuring more than 1,000 RSV awareness pledges.
- The Together Against RSV campaign unites families, healthcare partners and communities to spotlight the risks of RSV and its impact on all infants.
- Each magnetic hand symbolises a pledge of protection, creating an impactful visual reminder of the nation’s shared commitment to safeguarding young children’s health against RSV.
SINGAPORE – Media OutReach Newswire – 13 October 2025 – Sanofi has made history with a nationwide public health activation by clinching a spot in the Singapore Book of Records with the ‘Largest Mural of Magnetic Hands’, a public pledge against Respiratory Syncytial Virus (RSV) in its Together Against RSV campaign. The striking mural featured a total of over 1,000 hand pledges, each representing a parent, caregiver, or supporter who committed to raising awareness of Respiratory Syncytial Virus (RSV) – a common yet potentially serious virus – and protecting all infants from its risks.
Over the three-day event at Serangoon NEX, families, healthcare partners, and community members came together to symbolically place hand-shaped magnets on a panelled mural, with each hand carrying a personal pledge of commitment to learning about and fighting against RSV.
Zainab Sadat, Head of Vaccines, Sanofi Southeast Asia & India
“This record is more than just numbers; it is a symbol of unity and a testament to the collective power of Singaporean families, healthcare professionals, and communities coming together for a cause that truly matters. Through our ‘Together Against RSV’ campaign, we hope to spark ongoing conversations about RSV and empower parents with knowledge and preventive measures, including immunisation options, to protect their little ones. Together, we are building a future where every baby can breathe a little easier, and every family can rest a little more peacefully.”
The mural, measuring 2 meters tall by 5.1 meters wide, now serves as a striking visual reminder of the nation’s shared commitment to combating RSV. The event also complemented wider awareness initiatives, including collaborations with hospitals, parent communities, and an educational microsite (TogetherAgainstRSV.sg) in collaboration with the Singapore Paediatric Society, as part of Sanofi’s mission to empower parents with trusted information and preventive solutions.
Around the world, about two in three infants contract RSV before their first birthday1, making it the most common cause of lower respiratory tract infections, including bronchiolitis and pneumonia, in young children2. In Singapore, RSV is also a leading cause of infant hospitalisations, with the majority of cases occurring in otherwise healthy, full-term babies. Each year, an estimated 1,804 children under 29 months are hospitalised due to RSV-related illness3-7.
Hashtag: #Sanofi
The issuer is solely responsible for the content of this announcement.
About RSV
RSV is a highly contagious virus that can lead to serious respiratory illness for infants.2 It is a leading cause of hospitalisation in all infants, with most hospitalisations for RSV occurring in otherwise healthy infants born at term3-7. Two out of three infants are infected with RSV during their first year of life and almost all children are infected by their second birthday1. Globally, in 2019, there were approximately 33 million cases of acute lower respiratory infections leading to more than three million hospitalisations, and it was estimated that there were 26,300 in-hospital deaths of children younger than five years8. RSV-related direct medical costs, globally — including hospital, outpatient and follow-up care — were estimated at €4.82 billion in 20179.
About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
For more information, visit
www.sanofi.com.
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2022. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
References
- Walsh, EE. Respiratory Syncytial Virus Infection: An Illness for All Ages. Clinics in Chest Medicine. 2017;38(1):29-36.
- Karron A. Respiratory Syncytial Virus Vaccines and Monoclonal antibodies. Orenstein W, Offit P, Edwards KM, Plotkin S. Plotkin’s Vaccines, eighth edition: 998-1004. Elsevier 2023.
- Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143(5 Suppl):S127-S132. doi:10.1067/s00223476(03)00510-9.
- Zhou H, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012;54:1427–1436.
- Rha B, et al. Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015-2016. Pediatrics. 2020;146:e20193611.
- Arriola CS, et al. Estimated Burden of Community-Onset Respiratory Syncytial Virus-Associated Hospitalizations Among Children Aged <2 Years in the United States, 2014-15. J Pediatric Infect Dis Soc. 2020;9:587-595
- Tam CC, et al. Burden and Cost of Hospitalization for Respiratory Syncytial Virus in Young Children, Singapore. Emerg Infect Dis. 2020 Jul;26(7):1489-1496
- Li Y, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 2022;399:92047–64.
- Zhang S, et al. Cost of Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection Management in Young Children at the Regional and Global Level: A Systematic Review and Meta-Analysis. J Infect Dis. 2020;222(Suppl 7):S680-687.
MAT-SG-2500364-1.0-10/202
Media OutReach
OOm Institute Calls for AI Fluency to Close Human Critical Thinking Gap
The rapid adoption of AI tools without sufficient verification, contextual understanding, or critical oversight is contributing to a growing “Human Critical Thinking Gap”.
Recent research from Professors Rick Dakan and Joseph Feller also corroborates this; only 8.7% of participants consistently verified high-stakes AI-generated claims before accepting them.
Beyond the Prompt: The Human-Centric Shift
While prompt engineering remains a foundational skill for today’s workforce, OOm Institute suggests the discipline must evolve beyond simple input mechanics.
“We are entering a false competence trap,” says Ian Cheow, CEO at OOm Institute. “People are learning how to prompt, but they aren’t learning how to make the right decisions. If you cannot spot when an AI’s logic fails, you aren’t using a tool, you are delegating your intelligence.”
The Warning: If You Let AI Think for You, You “De-skill”
Professionals who rely heavily on AI without developing critical evaluation skills risk “de-skilling”, where domain expertise erodes over time due to over-dependence on automated systems.
The concept of AI Fluency is built around three core capabilities:
- Decision to Correct: The ability to determine when AI-generated output is sufficient and when it poses a risk that requires human revision or rejection.
- Contextual Sovereignty: Ensuring human oversight remains central so AI outputs align with Singapore’s cultural, commercial, and ethical contexts.
- Critical Inquiry: Moving beyond prompting to actively question assumptions, logic, accuracy, and completeness in AI-generated responses.
Real-World Practice vs Theory
As AI tools evolve rapidly, practitioners argue that effective AI capability cannot rely solely on static classroom theory. Real-world usage often involves changing workflows, unpredictable outputs, and context-specific decision-making that require continuous practical application and human judgment.
Maintaining AI fluency increasingly requires learning from practitioners actively applying these tools in commercial environments.
“At OOm Institute, our focus is on building practical decision-making in AI usage,” Mr Cheow added. “Our goal is to help professionals use AI with stronger critical thinking, clearer accountability, and practical business understanding.”
Hashtag: #aicourse #wsqaicourse #aisingapore #aifluency #aiskills
https://www.oom.com.sg/institute/
https://linkedin.com/company/oominstitute
https://www.facebook.com/oominstitute/
https://www.instagram.com/oominstitute/
The issuer is solely responsible for the content of this announcement.
OOm Institute
Media OutReach
Suanova, a Subsidiary of Yeebo, Signs Comprehensive Strategic Cooperation Agreement with InfiX.ai
Advancing Deployment of Training and Inference Integrated AI Platforms in Healthcare Applications, Powered by Domestic High-Density Computing Infrastructure
HONG KONG SAR – Media OutReach Newswire – 10 June 2026 – Yeebo (International Holdings) Limited (“Yeebo”; Stock Code: 00259.HK, together with its subsidiaries, the “Group”) is pleased to announce that its wholly-owned subsidiary, Suanova Technology Limited (“Suanova”), has entered into a comprehensive strategic cooperation agreement with InfiX.ai, a global leader in enterprise-grade generative AI (GenAI) infrastructure solutions. Leveraging Suanova’s Shanghai Cube, a domestically developed high-density computing infrastructure, the two parties will jointly advance the deployment of training and inference integrated AI platforms with continuous self-learning capabilities in healthcare applicatoins. As part of this collaboration, Suanova will contribute its expertise in domestic computing infrastructure by providing the core computing power and foundational support.
With healthcare as the initial focus, the two parties have already collaborated with leading medical institutions to conduct clinical validation in areas such as cancer GenAI, foundational medical Large Language Models (LLMs) and personalized cancer treatment planning.
Building Integrated Infrastructure for Medical AI with Shanghai Cube as the Foundation
The training and inference integrated AI platforms deployed under this collaboration are powered by Shanghai Cube, combined with InfiX.ai’s training, inference and multimodal AI capabilities. This integration delivers a truly unified hardware-software infrastructure tailored for medical AI applications.
Shanghai Cube, developed with the participation of Suanova, was among the earliest of its kind in China and is currently the highest-density domestically developed GPU supernode product. It adopts a high-density deployment architecture featuring 128 GPUs per rack with liquid cooling, enabling compact and efficient deployment of large-scale computing clusters. Shanghai Cube integrates a range of domestically produced core components, including liquid-cooling systems, high-performance parallel storage systems, retimers and motherboard capacitors. It provides a one-stop, highly efficient solution for the large-scale deployment of domestic computing systems and models.
Partnering with InfiX.ai to Build Enterprise-Grade AI Infrastructure
InfiX.ai is a research-driven AI infrastructure company serving global markets, with capabilities spanning IaaS, PaaS and MaaS. The company is building a Decentralized Co-GenAI Network that connects computing power, models, platforms and intelligent applications, with the aim of helping enterprises and organizations train, deploy and own their domain-specific AI based on proprietary data, expertise and business workflows.
InfiX.ai brings together world-class talent in AI research and industry deployment. The company is led by its Founder and Chief Scientist, Prof. Hongxia Yang, with Co-Founder and Vice President Haiqing Chen and Chief AI Architect Jianmin Wu forming the core management and technology team. Prof. Yang is also a Chair Professor at The Hong Kong Polytechnic University and is a globally recognized leader in artificial intelligence, with extensive experience spanning both academia and industry. She previously served as Head of LLMs in the at ByteDance (U.S.), AI Scientist and Director at Alibaba Group, Chief Data Scientist at Yahoo!, and Research Staff Member at IBM T.J. Watson Research Center. Prof. Yang has published more than 150 papers and holds over 50 patents. She has also received numerous international honors, including the WAIC SAIL Award, the National Scientific and Technological Progress Award, and recognition as one of the AI 2000 Most Influential Scholars worldwide.
By integrating InfiX.ai’s training and inference algorithms with Suanova’s high-performance computing platform, the solution significantly reduces memory usage and computing resource requirements. This enables higher throughput and supports training and deployment of larger-scale models under equivalent hardware configurations. The system is also capable of continuously capturing data for incremental training, integrating user feedback for fine-tuning and reinforcement learning, thereby ensuring that model performance evolves alongside changing business needs. Furthermore, the infrastructure supports local execution of the entire AI workflow – from training and fine-tuning to inference – thereby ensuring data security by design and meeting the stringent security requirements of sectors such as healthcare, finance, and government.
Mr. Daliang Chen, CEO of Suanova, said: “This partnership with InfiX.ai represents an important milestone in Suanova’s expansion into medical AI. Leveraging the Shanghai Cube high-density domestic computing platform, we aim to accelerate the adoption of medical AI in real-world clinical settings. This collaboration not only brings together the complementary strengths of both companies from a technological perspective, but also serves as a key step in advancing the domestic computing ecosystem. Looking ahead, we will continue to work closely with our partners to drive the deep integration of artificial intelligence across diverse industries.”
Hashtag: #Yeebo
The issuer is solely responsible for the content of this announcement.
About Yeebo (International Holdings) Limited
Founded in 1988, Yeebo (International Holdings) Limited is a diversified electronic component company with a well-established presence in the global market. The Company’s core business spans flat panel displays, computing power and capacitors, serving a broad spectrum of industrial and consumer applications. Headquartered in Hong Kong, Yeebo operates its manufacturing operations primarily in the Guangdong and Jiangsu provinces, supporting a global sales network that ensures localized service and support for its international clientele.
In alignment with its long-term strategic vision, Yeebo is leveraging its robust operational foundation to expand into the Artificial Intelligence (“AI”) compute and related sectors. This initiative reflects the Company’s commitment to innovation and technological advancement, with the objective of positioning Yeebo as a leading and influential participant in the rapidly evolving AI industry across mainland China and Hong Kong.
About Suanova Technology Limited
Suanova, under Yeebo, is an innovative technology company focused on delivering independent, efficient, and accessible domestic AI computing services. Its business spans three core areas: computing power and cloud operations, computing technology development and computing industry investment. With branches in Hong Kong and Shanghai, it provides customers with better localized services. It is committed to transforming complex AI infrastructure into simple, efficient, and cost‑effective services through continuous technological innovation, with the goal of becoming a leading “infrastructure operator” in the AI era.
Media OutReach
KAST chooses Elliptic digital asset decisioning for global AML and sanctions compliance
KAST has used Elliptic’s solutions since 2024 to screen wallets and monitor crypto transactions for indicators of financial crime as customers fund and use their KAST accounts. By integrating Elliptic’s blockchain intelligence into its risk and compliance stack, KAST has been able to identify high-risk activity in real-time, reduce exposure to sanctioned or illicit wallets and demonstrate robust controls to regulators and partners.
Founded in July 2024 by former Circle executive Raagulan Pathy, KAST provides USD-denominated accounts, global pay-ins and payouts to more than 170 countries, and a growing suite of consumer and business financial tools built on stablecoin rails rather than legacy settlement networks. With KAST, people can hold, send, and spend instantly while transacting with merchants and ATMs around the world.
Since launch, KAST has scaled to more than one million users and is processing about $5 billion in annualized transaction volume, reflecting the growing adoption of stablecoin-based financial services beyond trading and crypto-native use cases. In March, KAST announced a record $80 million Series A funding round, which is being deployed to expand across North America, Latin America and the Middle East. Elliptic’s analytics help KAST manage risk, applying a consistent, data-driven approach to AML and sanctions screening as the platform scales into new markets.
“Every time customers tap their card, send or receive transactions, they need to trust it’s safe,” said Pathy, Founder & CEO at KAST. “Our users rely on us for institution-grade security everywhere in the world. Elliptic is a key part of that promise. Their blockchain intelligence helps us detect fraud patterns, sanctioned activity and other red flags behind the scenes so that our customers feel safe and secure.”
“As stablecoin financial platforms like KAST reach more users, regulators and partners expect the same standard of financial crime controls that apply in traditional finance,” said James Smith, Co-Founder and Chief Strategy Officer at Elliptic. “KAST has been building with compliance in mind from day one. Through this partnership, we are helping to ensure the platform can scale while meeting regulatory expectations for AML and sanctions risk.”
Elliptic’s analytics now underpin KAST’s financial crime controls. Working alongside the platform’s identity, fraud and transaction monitoring solutions, Elliptic supports a consistent, risk-based approach to onboarding, funding and card usage as the platform scales.
Hashtag: #Elliptic
The issuer is solely responsible for the content of this announcement.
About Elliptic
Our platform’s unrivalled uptime, scalability, depth and breadth of our data and intelligence means exacting organizations choose Elliptic for their compliance, risk management, intelligence operations and blockchain infrastructure needs.
Founded in 2013, Elliptic is headquartered in London with offices in New York, Washington D.C., Miami, Dubai, Hong Kong, Singapore and Tokyo. To learn more, visit www.elliptic.co and follow us on
LinkedIn and
X.
About KAST
KAST is a stablecoin-powered financial platform that connects digital assets with traditional finance, enabling 1 million+ people to send, receive and convert funds across borders, currencies and payment rails through a single app. The company focuses on helping individuals and businesses earn globally and spend locally by combining instant peer-to-peer transfers with compliant access to local bank payouts in supported markets. Visit www.kast.xyz.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn
